MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 20, 2006--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today that it has begun treating patients in its multi-national phase 2/3 study evaluating the use of Ceflatonin(R) (homoharringtonine, HHT) in patients with chronic, accelerated and blast-phase chronic myeloid leukemia (CML) who have the T315I bcr-abl point mutation. That mutation is associated with resistance to Gleevec(R) and other tyrosine kinase inhibitor therapeutics recently approved or known to be in development, and it is increasing in prevalence among patients with CML.
